PVPatrick Vogel

Patrick Vogel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Patrick Vogel has a total of 140 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    First In-vivo Human Magnetic Particle Imaging

    by Patrick Vogel, Thomas Kampf, Martin Andreas Rückert, Johanna Günther, Teresa Reichl, Thorsten Bley, Volker C. Behr, Philipp Gruschwitz, Viktor Hartung

    Magnetic particle imaging (MPI) is a tracer-based imaging modality enabling radiation-free visualization of superparamagnetic iron oxide nanoparticles with high temporal resolution. Despite extensive preclinical development, in-vivo application in humans has not previously been reported so far. This study aimed to demonstrate the feasibility of first-in-human MPI angiography and to compare it with conventional X-ray digital subtraction angiography (DSA). A first-in-human MPI angiography was performed in a healthy volunteer using a human-scale interventional MPI scanner and clinically approved ferucarbotran tracer. Imaging of the upper extremity veins was conducted under clinical angiography laboratory conditions with continuous physiological monitoring. Conventional DSA of the same region was performed under identical procedural conditions for direct comparison. MPI data were acquired in real time with 2 frames per second and co-registered with DSA images. MPI successfully visualized major superficial and deep veins, including inflow, branching patterns, venous valve filling, collateral pathways, and tracer clearance dynamics. Spatial and temporal visualization was comparable to DSA for clinically relevant vascular structures. No adverse events occurred, and safety monitoring remained unremarkable throughout the procedure. This first in-vivo human demonstration shows that MPI enables real-time, radiation-free angiographic visualization of vascular structures with clinically relevant temporal resolution. MPI has potential as a novel imaging modality for selected vascular and interventional applications and represents an important step toward clinical translation.


  • Open Access

    Rigid-dipole magnetic nanoparticles for sub-second 3D viscosity imaging

    by J M Costa, G F Resende, Y Gu, S P Fernandes, J N M Silvares, M R Lagarto, F L Sousa, V M Gaspar, J Mano, A Millán, et al.

    Magnetic nanoparticles are widely explored in bio-related applications, as sensing probes, as local heat generators, and as contrast agents for imaging. The large majority of these nanoparticles are iron oxides and cubic ferrites with low to medium magnetic anisotropy, and thus a weak to medium coupling between spins and crystal lattice. Here we present stable aqueous colloidal suspensions made of a doped iron oxide (Al-doped ε-Fe2O3) with a strong coupling between the magnetic moment and the crystal lattice. We show that in stable aqueous suspensions, these highly anisotropic nanoparticles are cell-compatible and follow a rigid dipole model, enabling viscosity sensing, and viscosity imaging using a magnetic particle imaging (MPI) scanner. This opens new perspectives for bio-application of magnetic nanoparticles, such as 3D viscosity imaging with sub-second resolution using MPI, a tomographic technique with kHz imaging rates.

  • Open Access

    Analytical solution for the nonlinear rotation of a spherical magnetic particle in a rotating magnetic field

    by Thomas Kampf, Martin Andreas Rückert, Anna Vilter, Volker F.J. Sturm, Patrick Vogel, Volker Christian Behr

    The application of a weak rotating magnetic field to magnetic particles, that show only Brownian dynamics and are suspended in a liquid leads to a nonlinear rotation if the magnetic field is not strong enough to overcome the rotational friction at the applied frequency. In this paper, the analytical solution to the equation of motion is derived for the case of negligible angular momentum and no random thermal interactions. The former is an accurate approximation in all typical applications such as magnetic particle imaging or magnetic particle based hyperthermia. Having a closed solution for the theoretical edge case, where random thermal interactions go to zero, can be used as a verification tool for more generalized particle simulations and it can also be used as a basis for constructing approximations for more general cases.

  • Open Access

    Magnetic particle imaging angiography of the femoral artery in a human cadaveric perfusion model

    by Viktor Hartung, Philipp Gruschwitz, Anne Marie Augustin, Jan-Peter Grunz, Florian Kleefeldt, Dominik Peter, Süleyman Ergün, Johanna Günther, Teresa Reichl, Thomas Kampf, et al.

    Background: Magnetic particle imaging (MPI) allows for radiation-free visualization of tracers without background signal. With the first human-sized interventional MPI scanner being recently developed, the aim of the present study was to test its performance for guiding of endovascular procedures in a realistic perfusion model. Methods: Three fresh-frozen cadaveric legs were prepared to establish continuous circulation in the superficial femoral artery via introducer sheaths in the inguinal and infragenicular region. To facilitate vessel visualization, a mixture of a MPI tracer (Resotran® or Perimag®) and X-ray contrast agent was injected under continuous extracorporeal perfusion and imaged simultaneously with MPI angiography and digital subtraction angiography (DSA) as reference. Results: The MPI scanner integrates seamlessly into the standard operating procedures in the angiography suite and simultaneous imaging with DSA and MPI is feasible. The MPI scanner detects a tracer bolus of 2 ml Perimag® or 1.5 ml Resotran®. Imaging results are consistent and reproducible in three cadaveric leg phantoms. Conclusion: This study demonstrates, that the recently developed human-sized MPI scanner facilitates reliable radiation-free image guidance for peripheral vascular interventions in the superficial femoral artery with a tracer approved for use in humans.


  • Open Access

    Characterization of the clinically approved MRI tracer resotran for magnetic particle imaging in a comparison study

    by Fabian Mohn, Konrad Scheffler, Justin Ackers, Agnes Weimer, Franz Wegner, Florian Thieben, Mandy Ahlborg, Patrick Vogel, Matthias Graeser, Tobias Knopp

    Objective. The availability of magnetic nanoparticles (MNPs) with medical approval for human intervention is fundamental to the clinical translation of magnetic particle imaging (MPI). In this work, we thoroughly evaluate and compare the magnetic properties of an magnetic resonance imaging (MRI) approved tracer to validate its performance for MPI in future human trials. Approach. We analyze whether the recently approved MRI tracer Resotran is suitable for MPI. In addition, we compare Resotran with the previously approved and extensively studied tracer Resovist, with Ferrotran, which is currently in a clinical phase III study, and with the tailored MPI tracer Perimag. Main results. Initial magnetic particle spectroscopy (MPS) measurements indicate that Resotran exhibits performance characteristics akin to Resovist, but below Perimag. We provide data on four different tracers using dynamic light scattering, transmission electron microscopy, vibrating sample magnetometry measurements, MPS to derive hysteresis, point spread functions, and a serial dilution, as well as system matrix based MPI measurements on a preclinical scanner (Bruker 25/20 FF), including reconstructed images. Significance. Numerous approved MNPs used as tracers in MRI lack the necessary magnetic properties essential for robust signal generation in MPI. The process of obtaining medical approval for dedicated MPI tracers optimized for signal performance is an arduous and costly endeavor, often only justifiable for companies with a well-defined clinical business case. Resotran is an approved tracer that has become available in Europe for MRI. In this work, we study the eligibility of Resotran for MPI in an effort to pave the way for human MPI trials.


  • Open Access

    Characterization of the Clinically Approved MRI Tracer Resotran for Magnetic Particle Imaging in a Comparison Study

    by Fabian Mohn, Konrad Scheffler, Justin Ackers, Agnes Weimer, Franz Wegner, Florian Thieben, Mandy Ahlborg, Patrick Vogel, Matthias Graeser, Tobias Knopp

    Objective. The availability of magnetic nanoparticles with medical approval for human intervention is fundamental to the clinical translation of magnetic particle imaging (MPI). In this work, we thoroughly evaluate and compare the magnetic properties of an magnetic resonance imaging (MRI) approved tracer to validate its performance for MPI in future human trials. Approach. We analyze whether the recently approved MRI tracer Resotran is suitable for MPI. In addition, we compare Resotran with the previously approved and extensively studied tracer Resovist, with Ferrotran, which is currently in a clinical phase III study, and with the tailored MPI tracer Perimag. Main results. Initial magnetic particle spectroscopy measurements indicate that Resotran exhibits performance characteristics akin to Resovist, but below Perimag. We provide data on four different tracers using dynamic light scattering, transmission electron microscopy, vibrating sample magnetometry measurements, magnetic particle spectroscopy to derive hysteresis, point spread functions, and a serial dilution, as well as system matrix based MPI measurements on a preclinical scanner (Bruker 25/20 FF), including reconstructed images. Significance. Numerous approved magnetic nanoparticles used as tracers in MRI lack the necessary magnetic properties essential for robust signal generation in MPI. The process of obtaining medical approval for dedicated MPI tracers optimized for signal performance is an arduous and costly endeavor, often only justifiable for companies with a well-defined clinical business case. Resotran is an approved tracer that has become available in Europe for MRI. In this work, we study the eligibility of Resotran for MPI in an effort to pave the way for human MPI trials.

  • Top Cited Papers
    Open Access

    iMPI: portable human-sized magnetic particle imaging scanner for real-time endovascular interventions

    by P. Vogel, M. A. Rückert, C. Greiner, J. Günther, T. Reichl, T. Kampf, T. A. Bley, V. C. Behr, S. Herz

    Minimally invasive endovascular interventions have become an important tool for the treatment of cardiovascular diseases such as ischemic heart disease, peripheral artery disease, and stroke. X-ray fluoroscopy and digital subtraction angiography are used to precisely guide these procedures, but they are associated with radiation exposure for patients and clinical staff. Magnetic Particle Imaging (MPI) is an emerging imaging technology using time-varying magnetic fields combined with magnetic nanoparticle tracers for fast and highly sensitive imaging. In recent years, basic experiments have shown that MPI has great potential for cardiovascular applications. However, commercially available MPI scanners were too large and expensive and had a small field of view (FOV) designed for rodents, which limited further translational research. The first human-sized MPI scanner designed specifically for brain imaging showed promising results but had limitations in gradient strength, acquisition time and portability. Here, we present a portable interventional MPI (iMPI) system dedicated for real-time endovascular interventions free of ionizing radiation. It uses a novel field generator approach with a very large FOV and an application-oriented open design enabling hybrid approaches with conventional X-ray-based angiography. The feasibility of a real-time iMPI-guided percutaneous transluminal angioplasty (PTA) is shown in a realistic dynamic human-sized leg model.


  • Open Access

    iMPI – portable human-sized Magnetic Particle Imaging Scanner for real-time endovascular Interventions

    by Patrick Vogel, Martin Rückert, Christoph Greiner, Johanna Günther, Teresa Reichl, Thomas Kampf, Thorsten Bley, Volker Behr, Stefan Herz

    Minimally invasive endovascular interventions have become an important tool for the treatment of cardiovascular diseases such as ischemic heart disease, peripheral artery disease, and stroke. X-ray fluoroscopy and digital subtraction angiography are used to precisely guide these procedures, but they are associated with radiation exposure for patients and clinical staff. Magnetic Particle Imaging (MPI) is an emerging imaging technology using time-varying magnetic fields combined with magnetic nanoparticle tracers for fast and highly sensitive imaging. In recent years, basic experiments have shown that MPI has great potential for cardiovascular applications. However, current MPI scanners were too large, slow and expensive, and had a very small field of view (FOV), which limited further translational research. Here, we present a portable interventional MPI (iMPI) scanner dedicated for real-time endovascular interventions free of ionizing radiation. It uses a novel field generator approach with a very large FOV and an application-oriented open design enabling hybrid approaches with conventional X-ray-based angiography. The feasibility of a real-time iMPI-guided percutaneous transluminal angioplasty (PTA) is shown in a realistic dynamic human-sized leg model.


  • Open Access

    Critical Offset Magnetic PArticle SpectroScopy for rapid and highly sensitive medical point-of-care diagnostics

    by Patrick Vogel, Martin Andreas Rückert, Bernhard Friedrich, Rainer Tietze, Stefan Lyer, Thomas Kampf, Thomas Hennig, Lars Dölken, Christoph Alexiou, Volker Christian Behr

    Magnetic nanoparticles (MNPs) have been adapted for many applications, e.g., bioassays for the detection of biomarkers such as antibodies, by controlled engineering of specific surface properties. Specific measurement of such binding states is of high interest but currently limited to highly sensitive techniques such as ELISA or flow cytometry, which are relatively inflexible, difficult to handle, expensive and time-consuming. Here we report a method named COMPASS (Critical-Offset-Magnetic-Particle-SpectroScopy), which is based on a critical offset magnetic field, enabling sensitive detection to minimal changes in mobility of MNP ensembles, e.g., resulting from SARS-CoV-2 antibodies binding to the S antigen on the surface of functionalized MNPs. With a sensitivity of 0.33 fmole/50 µl (≙7 pM) for SARS-CoV-2-S1 antibodies, measured with a low-cost portable COMPASS device, the proposed technique is competitive with respect to sensitivity while providing flexibility, robustness, and a measurement time of seconds per sample. In addition, initial results with blood serum demonstrate high specificity.


  • Open Access

    COMPASS – rapid and highly sensitive medical point-of-care diagnostic

    by Patrick Vogel, Martin Rückert, Bernhard Friedrich, Rainer Tietze, Stefan Lyer, Thomas Kampf, Thomas Hennig, Lars Dölken, Christoph Alexiou, Volker Behr

    In the last decade Magnetic nanoparticles (MNPs) have gained an enormous interest in specialized areas such as medicine, cancer theranostics, biosensing, catalysis, agriculture, and the environmental protection. By controlled engineering of specific surface properties, named functionalization, MNPs are gaining special features for desired applications, e.g., bioassays for the detection of biomolecules or biomarkers such as antibodies. The characterization as well as a highly specific measurement of such binding states is of high interest and limited to highly sensitive techniques such as ELISA (Enzyme-linked Immunosorbent Assay) or flow cytometry, which are relatively inflexible, difficult to handle, expensive and time-consuming. Novel upcoming methods, such as ACS (AC susceptometry) or MPS (Magnetic Particle Spectroscopy), exploit the magnetization response of functionalized MNP ensembles to assess specific information about the MNP mobility within their environment as well as the conjugations of chemical or biological compounds on their surface. Both methods have shown promising results reaching similar sensitivities within short measurement times but showing difficulties in data interpretation. Here, we report a novel method, COMPASS (Critical Offset Magnetic PArticle SpectroScopy), which is based on a critical offset magnetic field of MNPs, which enables sensitive detection to minimal changes in mobility of MNP ensembles, e.g., resulting from SARS-CoV-2 antibodies binding to the S antigen on the surface of functionalized MNPs. With a validated sensitivity of 0.85 fmole/50 µl sample volume ( ≙ 33 pM) SARS-CoV-2-S1 antibodies, measured with a low-cost portable COMPASS device, the proposed technique is not only competitive with the sensitivity of commonly used ELISA or flow cytometry methods but provides more flexibility, robustness and rapid measurement withinwell below a minute per sample, including sample conjugation, mixing and incubation times. The underlying physical effect is based on an offset magnetic field induced suppression of a higher harmonic in the nonlinear magnetization response of the MNP to a time varying magnetic field resulting in a highly sensitive response of the signal phase to minimal changes in particle mobility. Since this effect is independent of MNP concentration, the sample handling is much simpler and robust. Our method thus may pave the way for deeper insights into complex and rapid binding dynamics of functionalization chemistry and can lead to a huge step forwards in point-of-care diagnostics as well as impacts other fields in research and industries.